cache/27db5e2dbf5e46db800bc7d2bf7716ea1ccf0234b2b9b91b108b4c9906493714

COM:IMMUTRIX

ImmutriX Therapeutics, Inc.

  • Privately Held

Company Overview

Metric
Company NameImmutriX Therapeutics, Inc.Fisher & Paykel Healthcare Corporation Limited
SymbolFPH
MSH IDCOM:IMMUTRIXCOM:FPHCARE
MarketPRIVATESTOCKS
SectorHealthcare & Health ServicesHealthcare
IndustryMedical DevicesMedical - Instruments & Supplies
CountryUSNZ
Stage
Employee Count6.98K
Websiteimmutrix.comfphcare.com
LinkedIn
Founders

Market Metrics

Metric
Market Cap10.75B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Financial Performance

Metric
Revenue1.03B
Revenue (LTM)
Revenue (NTM)
Gross Profit618.17M
EBITDA281.75M
Operating Income215.08M
Net Income77.35M
EPS0.13
Diluted EPS0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.60
Operating Profit Margin0.22
EBITDA Margin0.27
Net Profit Margin0.15
Return on Equity0.23
Return on Assets0.16
Return on Capital Employed0.34

Valuation Multiples

Metric
P/E Ratio57.63
P/B Ratio8.23
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio10.19
EV Multiple38.73

Operational Metrics

Metric
Days Sales Outstanding50.20
Days Payables Outstanding24.42
Days Inventory Outstanding192.47
Operating Cycle248.37
Cash Conversion Cycle134.69
Asset Turnover1.32

Cash Flow Metrics

Metric
Operating Cash Flow250.60M
Free Cash Flow52.85M
Cash Flow to Debt5.60
Operating Cash Flow/Sales0.25
Free Cash Flow Yield-0.01

Balance Sheet Metrics

Metric
Cash & Equivalents47.83M
Accounts Receivable-22.46M
Inventory186.90M
Goodwill
Debt to Capitalization0.13
Debt to Assets0.07
Current Ratio2.67
Quick Ratio1.16

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue0.11
SG&A to Revenue